15 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 20 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 15, Unknown 3, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
Follow Meningococcal Infections: new trials by email Literature Review of Meningococcal Infections trials Research Report on Meningococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine high-dose Group ACYW135X Meningococcal Conjugate Vaccine, medium-dose Group ACYW135X Meningococcal Conjugate Vaccine, low-dose Group ACYW135X Meningococcal Conjugate Vaccine - Meningococcal Meningitis | Phase 1 | Not yet recruiting | Sinovac Life Sciences Co., Ltd. | 150 | 2026-01-21 | 2026-01-28 |
| Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4), DTcP-Hib-MCV4, Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP) - Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis | Phase 1 | Recruiting | CanSino Biologics Inc. | 260 | 2025-12-19 | 2025-12-31 |
| Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old EuNmCV-5, Menveo - Infection, Meningococcal | Phase 1 | Completed | EuBiologics Co.,Ltd | 60 | 2023-02-28 | 2023-12-20 |
| A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo - Infections, Meningococcal | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 1440 | 2021-06-14 | 2025-05-31 |
| Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine, Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine - Infection, Meningococcal | Phase 1 | Completed | EuBiologics Co.,Ltd | 60 | 2020-09-01 | 2021-10-07 |
| Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population. Meningococcal Group ACYW135 Conjugate Vaccine - Meningococcal Infections | Phase 1 | Completed | Walvax Biotechnology Co., Ltd. | 100 | 2018-07-17 | 2020-01-22 |
| Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free), Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant) - Meningitis, Meningococcal Meningitis | Phase 1 / Phase 2 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 360 | 2016-08-01 | 2016-09-29 |
| Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months Meningococcal ACYW135 Polysaccharide Conjugate Vaccine - Meningitis, Meningococcal | Phase 1 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 200 | 2016-06-01 | 2016-08-26 |
| Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R, Investigational MenC-CRM adjuavnted with 25 ug of LHD153R, Investigational MenC-CRM adjuavnted with 50 ug of LHD153R - Infections, Meningococcal | Phase 1 | Completed | GlaxoSmithKline | 80 | 2016-03-01 | 2019-06-28 |
| A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine freeze-dried group ACYW135 MCV - Meningococcal Meningitis | Phase 1 | Unknown | Lanzhou Institute of Biological Products Co., Ltd | 200 | 2015-06-01 | 2015-06-25 |
| Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos 'MenCC-Bio', MENJUGATE - Meningitis, Meningococcal, Serogroup C | Phase 1 | Completed | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 60 | 2014-05-01 | 2015-09-16 |
| Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines MEN-ACYW135 reduced-dose intradermal administration - Meningococcal Disease | Phase 1 / Phase 2 | Completed | Leiden University Medical Center | 12 | 2013-01-01 | 2014-10-29 |
| Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis meningococcal meningitis conjugate vaccine, quadrivalent - Meningococcal Meningitis, Meningococcal Infections | Phase 1 | Completed | JN-International Medical Corporation | 60 | 2011-11-01 | 2013-01-14 |
| Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults rLP2086 vaccine or control - Meningitis, Meningococcal | Phase 1 | Completed | Pfizer | 48 | 2009-04-01 | 2015-08-06 |
| Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults meningococcal B rLP2086 vaccine candidate, Blood draw - Meningitis, Meningococcal | Phase 1 / Phase 2 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 60 | 2008-10-01 | 2011-08-23 |
| Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers Meningococcal Polysaccharide Tetanus Protein Conjugate, Meningococcal polysaccharide group C conjugated - Meningitis, Meningococcal Infection | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 360 | 2008-04-01 | 2018-02-06 |
| Phase 1 Safety and Immunogenicity of Meningococcal Vaccine 10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine - Meningococcal Infection, Group B | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 36 | 2008-04-01 | 2017-12-18 |
| Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide, Menactra®: Polysaccharide Diphtheria Toxoid Conjugate - Meningococcal Infections, Meningococcal Meningitis | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 216 | 2007-10-01 | 2013-09-20 |
| Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults MnB rLP2086 - Meningitis, Meningococcal | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 108 | 2006-03-01 | 2007-12-05 |
| Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis. 25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine, 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine - Meningitis, Meningococcal, Serogroup B | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 34 | 2005-12-05 | 2018-10-29 |
Meningitis, Meningococcal (13) · Meningitis (3) · Central Nervous System Infections (1) · Diphtheria (1) · Haemophilus Infections (1) · Tetanus (1)
Bacterial Infections (20) · Bacterial Infections and Mycoses (20) · Gram-Negative Bacterial Infections (20) · Infections (20) · Neisseriaceae Infections (20) · Nervous System Diseases (14) · Neuroinflammatory Diseases (14) · Central Nervous System Bacterial Infections (13) · Central Nervous System Diseases (13) · Meningitis, Bacterial (13) · Central Nervous System Infections (12) · Meningitis (11) · Actinomycetales Infections (1) · Clostridium Infections (1)
Meningococcal Vaccines (5) · Saline Solution (2) · Vaccines, Conjugate (2) · 4CMenB vaccine (1) · Blood Specimen Collection (1) · CRM197 (non-toxic variant of diphtheria toxin) (1) · HibTITER protein, Haemophilus influenzae (1) · Sodium Chloride (1) · Vaccines (1) · Vaccines, Combined (1)
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2) · EuBiologics Co.,Ltd (2) · GlaxoSmithKline (2) · Sanofi Pasteur, a Sanofi Company (2) · U.S. Army Medical Research and Development Command (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · CanSino Biologics Inc. (1) · JN-International Medical Corporation (1) · Lanzhou Institute of Biological Products Co., Ltd (1) · Leiden University Medical Center (1) · Pfizer (1) · Sinovac Life Sciences Co., Ltd. (1) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1) · Walvax Biotechnology Co., Ltd. (1)
United States (6) · China (5) · Australia (4) · Brazil (2) · South Korea (2) · Belgium (1) · Finland (1) · Germany (1) · Netherlands (1) · Poland (1) · Sweden (1) · Turkey (Türkiye) (1)
Barnett Gibbs, MD (1) · Leo Visser, MD, PhD (1) · Paul B Keiser (1) · Paul B Keiser, M.D. (1) · Sudesh Nagavalli, MD (1) · YJ Choi (1) · YJ Lee (1) · Yanxia Wang (1)
PMID 35164991, PMID 22094636, PMID 22832260, PMID 23352429, PMID 29778515, PMID 31669193, PMID 36564274, PMID 39112515
2014 (1)